Mouhamed Sabouni
Interventional Cardiology · Birmingham, ALNPI 1871911263
Payments from drug & device makers
What this record shows
This record is dominated by grants: $37,137 of the $43,701 with a category attached, or 85.0%. 17 manufacturers reported payments, led by Abbott at 36.0% of the total. Reporting peaked in 2021 at $37,559 and has fallen 97.6% since, to $919 in 2025.
Across 113 payments — averaging $386.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$16K
- Boston Scientific$13K
- Medtronic$11K
- Philips North America LLC$1K
- Edwards Lifesciences$1K
- Angiodynamics, Inc.$434
- plus $441 from 11 others
What the payments were for
- Consulting fees$4301%
- Grants$37,13785%
- Travel & lodging$2,4906%
- Food & beverage$3,5638%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 52 | $15,731 |
| Boston Scientific | 9 | $13,112 |
| Medtronic(2 entities) | 8 | $11,331 |
| Philips North America LLC | 6 | $1,457 |
| Edwards Lifesciences | 11 | $1,194 |
| Angiodynamics, Inc. | 4 | $434 |
| Pfizer | 9 | $125 |
| Chiesi USA, Inc. | 2 | $65 |
| Amgen | 2 | $52 |
| Janssen Scientific Affairs, LLC | 1 | $42 |
| Alnylam Pharmaceuticals Inc. | 2 | $37 |
| Johnson & Johnson | 1 | $33 |
| AstraZeneca | 2 | $26 |
| Shockwave Medical, Inc | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,701 in reported general payments places this provider in the 85th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 32 | $18,395 |
| Atorvastatin Calcium | 14 | $261 |
| ClopidogrelClopidogrel Bisulfate | 16 | $149 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Birmingham
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- Abdullah MahmoodBirmingham$61K
- Ali EbrahimiBirmingham$55K
- Jacob TownsendBirmingham$52K
- Kamran AliBirmingham$47K
- David SchultzBirmingham$19K
- Tushar MishraBirmingham$17K
- Arka ChatterjeeBirmingham$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.